The ASCO Post highlighted the extraordinary response to targeted therapy of a patient with an adult medulloblastoma brain tumor, the first such report in the first-line setting using hedgehog inhibitor vismodegib (Erivedge). The case report was published in Cancer Biology & Therapy, by Emil Lou, Assistant Professor of Medicine, University of Minnesota. The patient is doing well and is cancer-free several years later.
